论文部分内容阅读
多巴胺促效剂已广泛用于抑制高催乳素(PRL)血症病人的催乳素分泌,最近一些作者有力地证实了溴隐亭和其他多巴胺促效剂能使产生PRL的大腺瘤体积缩小。作者用光学显微镜和电子显微镜观察6例产生PRL的垂体腺瘤,对溴隐亭的作用有了进一步认识。 6例病人经蝶骨手术均确诊为大的垂体催乳素腺瘤,并有明显的高催乳素血症(420～9,800ng/ml),每例均经CT扫描。2例术前未用溴隐亭治疗。4例用溴隐亭治疗4～6周,其中2例在治疗6周末作了手术,并在治疗前和治疗结束时作生化和放射学检查;余2例在停用溴隐亭1或2周时作了手术。4例用溴隐亭治疗后的病人,血清PRL水平降低,放射学检查瘤体缩小,2例手术前停止1～2周溴隐亭治
Dopamine agonists have been widely used to inhibit prolactin secretion in patients with hyperprolactinemia (PRL). Some authors have recently demonstrated that bromocriptine and other dopamine agonists can reduce the volume of PRL-producing macroadenomas. The authors observed with light microscope and electron microscope six cases of PRL pituitary adenoma, the role of bromocriptine have been further understanding. All 6 patients were diagnosed as large pituitary prolactinomas by transsphenoidal surgery with obvious hyperprolactinemia (420 ~ 9,800 ng / ml), with CT scan in each case. Two cases were not treated with bromocriptine before surgery. 4 cases were treated with bromocriptine for 4 to 6 weeks, of which 2 cases were operated on at the end of 6 weeks and were biochemically and radiologically examined before treatment and at the end of treatment; the other 2 cases were stopped using bromocriptine 1 or 2 Week surgery. In 4 patients treated with bromocriptine, serum PRL levels decreased, radiological examination of the tumor narrowed, and 2 patients stopped before surgery for 1 to 2 weeks bromocriptine